Skip to content

Study · Case report or series · n = 1 · 1987

4 results

Intranasal oxytocin in obsessive-compulsive disorder.

Ansseau M, Legros JJ, Mormont C, Cerfontaine JL, Papart P, Geenen V, Adam F, Franck G

Psychoneuroendocrinology1 Jan 1987Cited by 51 (Europe PMC)

PMID3615752 (opens in a new tab)DOI10.1016/0306-4530(87)90009-6 (opens in a new tab)PepBankPUB-03615752
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In one patient with obsessive-compulsive disorder, 4 weeks of intranasal oxytocin gave clear improvement compared with 4 weeks of intranasal placebo.

    In plain wordsIn one patient with obsessive-compulsive disorder, nasal oxytocin improved symptoms more than nasal placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseObsessive-compulsive symptoms
    Study

    n = 1

    Comparator
    Intranasal placebo for 4 weeks
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    A 55-year patient with obsessive-compulsive disorder showed clear improvement during 4 weeks of treatment with intranasal oxytocin compared to 4 weeks of intranasal placebo.
  2. 02HumanCase report or seriesSafety outcome

    In one patient with obsessive-compulsive disorder, intranasal oxytocin treatment was accompanied by severe memory disturbances.

    In plain wordsIn one patient, nasal oxytocin came with severe memory problems.

    Peptide
    Oxytocin
    Outcome
    IncreaseMemory disturbances
    Study

    n = 1

    Comparator
    Intranasal placebo for 4 weeks
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    This improvement was concurrent with the development of severe memory disturbances, supporting the amnestic properties of the peptide.
    1 context sentence
    Summary · context
    A 55-year patient with obsessive-compulsive disorder showed clear improvement during 4 weeks of treatment with intranasal oxytocin
  3. 03HumanCase report or seriesSafety outcome

    In one patient with obsessive-compulsive disorder, intranasal oxytocin treatment was accompanied by psychotic symptoms.

    In plain wordsIn one patient, nasal oxytocin came with psychotic symptoms.

    Peptide
    Oxytocin
    Outcome
    IncreasePsychotic symptoms
    Study

    n = 1

    Comparator
    Intranasal placebo for 4 weeks
    Outcome group
    Adverse events · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    the patient also developed psychotic symptoms
  4. 04HumanCase report or seriesSafety outcome

    In one patient with obsessive-compulsive disorder, intranasal oxytocin treatment was accompanied by a marked decrease in plasma sodium and osmolality.

    In plain wordsIn one patient, nasal oxytocin came with a marked drop in blood sodium and osmolality.

    Peptide
    Oxytocin
    Outcome
    DecreasePlasma sodium and osmolality
    Study

    n = 1

    Comparator
    Intranasal placebo for 4 weeks
    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    a marked decrease in plasma sodium and osmolality, which may have masked the obsessive symptomatology.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:52 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.